Treatment of intraocular retinoblastoma with vincristine and carboplatin

Carlos Rodriguez-Galindo, Matthew W. Wilson, Barrett G. Haik, Thomas E. Merchant, Catherine A. Billups, Nirali Shah, Alvida Cain, James Langston, Mindy Lipson, Larry E. Kun, Charles B. Pratt

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy of chemoreduction using vincristine and carboplatin in preventing or delaying external-beam radiotherapy (EBRT) or enucleation in patients with intraocular retinoblastoma. Patients and Methods: Twenty-five patients (43 eyes) with newly diagnosed intraocular retinoblastoma received primary treatment with eight courses of vincristine and carboplatin. Focal treatments were delayed until documentation of disease progression. Outcome measures for each eye were length of time to disease progression, avoidance or delay of EBRT, and globe survival. Event-free survival was defined as the length of time to EBRT or enucleation. Results: Disease in all eyes responded to chemotherapy and progressed in only two patients before completion of the eight courses of therapy. Disease in all but four eyes progressed and required focal treatments. Event-free survival estimates at 2 years were 59.2% ± 12.0% for Reese-Ellsworth group I, II, and III eyes and 26.3% ± 9.2% for group IV and V eyes. Nineteen eyes (44.2%) required EBRT and 13 eyes (30.2%) were enucleated. The ocular salvage rate was 83.3% for Reese-Ellsworth group I to III eyes and 52.6% for group IV and V eyes. For those patients receiving EBRT, the median time from enrollment to EBRT was 9.5 months (median age at EBRT, 21 months). Conclusion: In combination with appropriate early intensive focal treatments, chemoreduction with vincristine and carboplatin, without etoposide, may be an alternative treatment for patients with early-stage intraocular retinoblastoma, although additional studies are needed. Patients with advanced intraocular disease require more aggressive treatments.

Original languageEnglish (US)
Pages (from-to)2019-2025
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number10
DOIs
StatePublished - May 15 2003

Fingerprint

Retinoblastoma
Carboplatin
Vincristine
Radiotherapy
Therapeutics
Disease-Free Survival
Disease Progression
Etoposide
Documentation
Outcome Assessment (Health Care)
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rodriguez-Galindo, C., Wilson, M. W., Haik, B. G., Merchant, T. E., Billups, C. A., Shah, N., ... Pratt, C. B. (2003). Treatment of intraocular retinoblastoma with vincristine and carboplatin. Journal of Clinical Oncology, 21(10), 2019-2025. https://doi.org/10.1200/JCO.2003.09.103

Treatment of intraocular retinoblastoma with vincristine and carboplatin. / Rodriguez-Galindo, Carlos; Wilson, Matthew W.; Haik, Barrett G.; Merchant, Thomas E.; Billups, Catherine A.; Shah, Nirali; Cain, Alvida; Langston, James; Lipson, Mindy; Kun, Larry E.; Pratt, Charles B.

In: Journal of Clinical Oncology, Vol. 21, No. 10, 15.05.2003, p. 2019-2025.

Research output: Contribution to journalArticle

Rodriguez-Galindo, C, Wilson, MW, Haik, BG, Merchant, TE, Billups, CA, Shah, N, Cain, A, Langston, J, Lipson, M, Kun, LE & Pratt, CB 2003, 'Treatment of intraocular retinoblastoma with vincristine and carboplatin', Journal of Clinical Oncology, vol. 21, no. 10, pp. 2019-2025. https://doi.org/10.1200/JCO.2003.09.103
Rodriguez-Galindo C, Wilson MW, Haik BG, Merchant TE, Billups CA, Shah N et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. Journal of Clinical Oncology. 2003 May 15;21(10):2019-2025. https://doi.org/10.1200/JCO.2003.09.103
Rodriguez-Galindo, Carlos ; Wilson, Matthew W. ; Haik, Barrett G. ; Merchant, Thomas E. ; Billups, Catherine A. ; Shah, Nirali ; Cain, Alvida ; Langston, James ; Lipson, Mindy ; Kun, Larry E. ; Pratt, Charles B. / Treatment of intraocular retinoblastoma with vincristine and carboplatin. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 10. pp. 2019-2025.
@article{3b8a99053fab4efdad3c896e29cbd121,
title = "Treatment of intraocular retinoblastoma with vincristine and carboplatin",
abstract = "Purpose: To evaluate the efficacy of chemoreduction using vincristine and carboplatin in preventing or delaying external-beam radiotherapy (EBRT) or enucleation in patients with intraocular retinoblastoma. Patients and Methods: Twenty-five patients (43 eyes) with newly diagnosed intraocular retinoblastoma received primary treatment with eight courses of vincristine and carboplatin. Focal treatments were delayed until documentation of disease progression. Outcome measures for each eye were length of time to disease progression, avoidance or delay of EBRT, and globe survival. Event-free survival was defined as the length of time to EBRT or enucleation. Results: Disease in all eyes responded to chemotherapy and progressed in only two patients before completion of the eight courses of therapy. Disease in all but four eyes progressed and required focal treatments. Event-free survival estimates at 2 years were 59.2{\%} ± 12.0{\%} for Reese-Ellsworth group I, II, and III eyes and 26.3{\%} ± 9.2{\%} for group IV and V eyes. Nineteen eyes (44.2{\%}) required EBRT and 13 eyes (30.2{\%}) were enucleated. The ocular salvage rate was 83.3{\%} for Reese-Ellsworth group I to III eyes and 52.6{\%} for group IV and V eyes. For those patients receiving EBRT, the median time from enrollment to EBRT was 9.5 months (median age at EBRT, 21 months). Conclusion: In combination with appropriate early intensive focal treatments, chemoreduction with vincristine and carboplatin, without etoposide, may be an alternative treatment for patients with early-stage intraocular retinoblastoma, although additional studies are needed. Patients with advanced intraocular disease require more aggressive treatments.",
author = "Carlos Rodriguez-Galindo and Wilson, {Matthew W.} and Haik, {Barrett G.} and Merchant, {Thomas E.} and Billups, {Catherine A.} and Nirali Shah and Alvida Cain and James Langston and Mindy Lipson and Kun, {Larry E.} and Pratt, {Charles B.}",
year = "2003",
month = "5",
day = "15",
doi = "10.1200/JCO.2003.09.103",
language = "English (US)",
volume = "21",
pages = "2019--2025",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Treatment of intraocular retinoblastoma with vincristine and carboplatin

AU - Rodriguez-Galindo, Carlos

AU - Wilson, Matthew W.

AU - Haik, Barrett G.

AU - Merchant, Thomas E.

AU - Billups, Catherine A.

AU - Shah, Nirali

AU - Cain, Alvida

AU - Langston, James

AU - Lipson, Mindy

AU - Kun, Larry E.

AU - Pratt, Charles B.

PY - 2003/5/15

Y1 - 2003/5/15

N2 - Purpose: To evaluate the efficacy of chemoreduction using vincristine and carboplatin in preventing or delaying external-beam radiotherapy (EBRT) or enucleation in patients with intraocular retinoblastoma. Patients and Methods: Twenty-five patients (43 eyes) with newly diagnosed intraocular retinoblastoma received primary treatment with eight courses of vincristine and carboplatin. Focal treatments were delayed until documentation of disease progression. Outcome measures for each eye were length of time to disease progression, avoidance or delay of EBRT, and globe survival. Event-free survival was defined as the length of time to EBRT or enucleation. Results: Disease in all eyes responded to chemotherapy and progressed in only two patients before completion of the eight courses of therapy. Disease in all but four eyes progressed and required focal treatments. Event-free survival estimates at 2 years were 59.2% ± 12.0% for Reese-Ellsworth group I, II, and III eyes and 26.3% ± 9.2% for group IV and V eyes. Nineteen eyes (44.2%) required EBRT and 13 eyes (30.2%) were enucleated. The ocular salvage rate was 83.3% for Reese-Ellsworth group I to III eyes and 52.6% for group IV and V eyes. For those patients receiving EBRT, the median time from enrollment to EBRT was 9.5 months (median age at EBRT, 21 months). Conclusion: In combination with appropriate early intensive focal treatments, chemoreduction with vincristine and carboplatin, without etoposide, may be an alternative treatment for patients with early-stage intraocular retinoblastoma, although additional studies are needed. Patients with advanced intraocular disease require more aggressive treatments.

AB - Purpose: To evaluate the efficacy of chemoreduction using vincristine and carboplatin in preventing or delaying external-beam radiotherapy (EBRT) or enucleation in patients with intraocular retinoblastoma. Patients and Methods: Twenty-five patients (43 eyes) with newly diagnosed intraocular retinoblastoma received primary treatment with eight courses of vincristine and carboplatin. Focal treatments were delayed until documentation of disease progression. Outcome measures for each eye were length of time to disease progression, avoidance or delay of EBRT, and globe survival. Event-free survival was defined as the length of time to EBRT or enucleation. Results: Disease in all eyes responded to chemotherapy and progressed in only two patients before completion of the eight courses of therapy. Disease in all but four eyes progressed and required focal treatments. Event-free survival estimates at 2 years were 59.2% ± 12.0% for Reese-Ellsworth group I, II, and III eyes and 26.3% ± 9.2% for group IV and V eyes. Nineteen eyes (44.2%) required EBRT and 13 eyes (30.2%) were enucleated. The ocular salvage rate was 83.3% for Reese-Ellsworth group I to III eyes and 52.6% for group IV and V eyes. For those patients receiving EBRT, the median time from enrollment to EBRT was 9.5 months (median age at EBRT, 21 months). Conclusion: In combination with appropriate early intensive focal treatments, chemoreduction with vincristine and carboplatin, without etoposide, may be an alternative treatment for patients with early-stage intraocular retinoblastoma, although additional studies are needed. Patients with advanced intraocular disease require more aggressive treatments.

UR - http://www.scopus.com/inward/record.url?scp=0038011920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038011920&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.09.103

DO - 10.1200/JCO.2003.09.103

M3 - Article

C2 - 12743157

AN - SCOPUS:0038011920

VL - 21

SP - 2019

EP - 2025

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -